YES....!!!
Wilson's HTM have upgraded their recommendation to a Strong BUY, as AVX’s major competitor in the HIV market – Incyte – had its Reverset product knocked
back from Phase III trials by the US FDA!!!
make sense now !!!
flying high this week, page-3
-
- There are more pages in this discussion • 12 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)